Abstract
A series of N-aroylated isatins 1-15 was synthesized and evaluated for their antiglycation activity. All compounds showed a varying degree of glycation inhibitory activity with IC50 values between 18.01 ± 0.05-693.7 ± 3.0 μM, when compared with the standard (aminoguanidine) having an IC50 = 268.7 ± 12.4 μM. Compound 1 was found to be the most active member of this series with an IC50 = 18.01 ± 0.05 μM. Compound 10 showed an IC50 = 72.5 ± 0.09 μM, whereas compound 7 has an IC50 = 80.18 ± 0.07 μM. Compounds 3, 9, and 13 showed IC50 values 170.2 ± 0.62, 117.91 ± 2.9, 171.3 ± 0.79 μM, respectively. Rest of the compounds along with parent isatin were found to be inactive. The structures of all the synthetic compounds were deduced by spectroscopic analysis.
Keywords: Isatin, N-Aroylation, Antiglycation, Lead molecules
Letters in Drug Design & Discovery
Title: N-Aroylated Isatins: Antiglycation Activity
Volume: 7 Issue: 3
Author(s): Khalid Mohammed Khan, Uzma Rasool Mughal, Ambreen Khan, Farzana Naz, Shahnaz Perveen and M. Iqbal Choudhary
Affiliation:
Keywords: Isatin, N-Aroylation, Antiglycation, Lead molecules
Abstract: A series of N-aroylated isatins 1-15 was synthesized and evaluated for their antiglycation activity. All compounds showed a varying degree of glycation inhibitory activity with IC50 values between 18.01 ± 0.05-693.7 ± 3.0 μM, when compared with the standard (aminoguanidine) having an IC50 = 268.7 ± 12.4 μM. Compound 1 was found to be the most active member of this series with an IC50 = 18.01 ± 0.05 μM. Compound 10 showed an IC50 = 72.5 ± 0.09 μM, whereas compound 7 has an IC50 = 80.18 ± 0.07 μM. Compounds 3, 9, and 13 showed IC50 values 170.2 ± 0.62, 117.91 ± 2.9, 171.3 ± 0.79 μM, respectively. Rest of the compounds along with parent isatin were found to be inactive. The structures of all the synthetic compounds were deduced by spectroscopic analysis.
Export Options
About this article
Cite this article as:
Khan Mohammed Khalid, Mughal Rasool Uzma, Khan Ambreen, Naz Farzana, Perveen Shahnaz and Choudhary Iqbal M., N-Aroylated Isatins: Antiglycation Activity, Letters in Drug Design & Discovery 2010; 7 (3) . https://dx.doi.org/10.2174/157018010790596597
DOI https://dx.doi.org/10.2174/157018010790596597 |
Print ISSN 1570-1808 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-628X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Receptor to Glutamate NMDA-Type: The Functional Diversity of the NR1 Isoforms and Pharmacological Properties
Current Pharmaceutical Design Editorial (Hot Topic: Regenerative Medicine in Neurological Diseases)
Recent Patents on Regenerative Medicine Role of Microfluidics in Blood-Brain Barrier Permeability Cell Culture Modeling: Relevance to CNS Disorders
CNS & Neurological Disorders - Drug Targets Diabetes Mellitus and Vascular Endothelial Dysfunction: Current Perspectives
Current Vascular Pharmacology The Role of Diabetes Mellitus in Diseases of the Gallbladder and Biliary Tract
Current Diabetes Reviews Mini-Review: Nucleus-Targeted Ribonucleases As Antitumor Drugs
Current Medicinal Chemistry A New Drug Candidate (GEMSP) for Multiple Sclerosis
Current Medicinal Chemistry Current Overview of Inorganic Nanoparticles for the Treatment of Central Nervous System (CNS) Diseases
Current Nanomaterials Definitions of Metabolic Syndrome: Where are We Now?
Current Vascular Pharmacology PET Studies of Brain Monoamine Transporters
Current Pharmaceutical Design The Role of Microglial Cell Subsets in Alzheimers Disease
Current Alzheimer Research Neuroprotective Effects of Fisetin in Alzheimer’s and Parkinson’s Diseases: From Chemistry to Medicine
Current Topics in Medicinal Chemistry Herbal and Traditional Chinese Medicine for the Treatment of Cardiovascular Complications in Diabetes Mellitus
Current Diabetes Reviews Cannabinoids and Neuro-Inflammation: Regulation of Brain Immune Response
Recent Patents on CNS Drug Discovery (Discontinued) Genetics and Diabetic Retinopathy
Current Diabetes Reviews Oxidative Stress Modulation Through Habitual Physical Activity
Current Pharmaceutical Design Basic and Clinical Aspects of Gene Therapy for Retinopathy Induced by Diabetes
Current Gene Therapy Potential Therapeutic Targets for Neurodegenerative Diseases: Lessons Learned from Calorie Restriction
Current Drug Targets Current Therapeutic Molecules and Targets in Neurodegenerative Diseases Based on in silico Drug Design
Current Neuropharmacology Large-Conductance Ca2+-Activated K+ Channels:Physiological Role and Pharmacology
Current Medicinal Chemistry